Complementary medicines in psychiatry: Review of effectiveness and safety
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: The use of complementary medicines in those with mental health problems is well documented. However, their effectiveness is often not established and they may be less harmless than commonly assumed. Aims: To review the complementary medicines routinely encountered in psychiatric practice, their effectiveness, potential adverse effects and interactions. Method: Electronic and manual literature search on the effectiveness and safety of psychotropic complementary medicines. Results: Potentially useful substances include ginkgo and hydergine as cognitive enhancers, passion flower and valerian as sedatives, St John's wort and sadenosylmethionine as antidepressants, and selenium and folate to complement antidepressants. The evidence is less conclusive for the use of omega-3 fatty acids as augmentation treatment in schizophrenia, melatonin for tardive dyskinesia and 18-methoxycoronaridine, an ibogaine derivative, for the treatment of cocaine and heroin addiction. Conclusions: Systematic clinical trials are needed to test promising substances. Meanwhile, those wishing to take psychotropic complementary medicines require appropriate advice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Unconventional medicine in the United States-Prevalence, costs, and patterns of use
Eisenberg, D. M., Kessler, R. C., Foster, C., Norlock, F. E., Calkins, D. R., & Delbanco, T. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301283280406 · Cited by 4,177 · cited 1×
“Their use by those with chronic disorders such as cancers, with their associated physical and psychological problems, is well documented (Eisenberg et al, 1993; Ernst & Cassileth, 1999).”
BackgroundA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“The results for panax ginseng and vitamin E were inconclusive (Sano et al, 1997; Vogeler et al, 1999).”
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Miller, L. G. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.20.2200 · Cited by 809
Roberts, C. G., & Ladenson, P. W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15696-1 · Cited by 567
Essential Fatty Acids and the Brain
Haag, M. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800308 · Cited by 421
A Multicenter, Placebo-controlled Trial of Melatonin for Sleep Disturbance in Alzheimer's Disease
Singer, C., Tractenberg, R. E., Kaye, J., Schafer, K., Gamst, A., Grundman, M., Thomas, R., & Thal, L. J. (2003) · Sleep · doi:10.1093/sleep/26.7.893 · Cited by 407
Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence,,,
Mischoulon, D., & Fava, M. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.5.1158s · Cited by 285
S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies
Bressa, G. M. (1994) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb05403.x · Cited by 195
Diaper, A., & Hindmarch, I. (2004) · Phytotherapy Research · doi:10.1002/ptr.1574 · Cited by 89
Mash, D. C., Staley, J. K., Pablo, J. P., Holohean, A. M., Hackman, J. C., & Davidoff, R. A. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11608-y · Cited by 80
Cited by
Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review
Izzo, A. A., & Ernst, E. (2009) · Drugs · doi:10.2165/11317010-000000000-00000 · Cited by 801
Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5100 · Cited by 438
Singh, S. K., Srivastav, S., Castellani, R. J., Plascencia-Villa, G., & Perry, G. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00767-8 · Cited by 401
Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview
Mazza, M., Pomponi, M., Janiri, L., Bria, P., & Mazza, S. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.07.010 · Cited by 306
Epigenetics in Alzheimer’s Disease: Perspective of DNA Methylation
Qazi, T. J., Quan, Z., Mir, A., & Qing, H. (2018) · Molecular Neurobiology · doi:10.1007/s12035-016-0357-6 · Cited by 153
Metadata
- Authors
- Werneke, U., Turner, T., & Priebe, S.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2006-02
- Volume
- 188
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1935081419
- Cited by
- 98
- References
- 12
- FWCI
- 24.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.